MT204, a humanized antibody with the potential to treat a variety of acute and chronic inflammatory diseases, including rheumatoid arthritis, asthma, acute transplant rejection, uveitis, psoriasis and multiple sclerosis. This antibody is the first to target human and non-human primate IL-2 by a unique mode of action, and has been shown in preclinical models to have inhibitory properties superior to those of a commercial IL-2 receptor-blocking antibody. 

MT228 (MORAb-028), a human IgM monoclonal antibody specific for a a cell-surface antigen present on human melanomas and tumors of neuroectodermal origin.

MT111, a BiTE antibody for treatment of human cancers expressing carcino embryonal antigen (CEA).